Literature DB >> 25987981

Abaloparatide: a new anabolic therapy on the horizon.

Felicia Cosman1.   

Abstract

Year:  2015        PMID： 25987981      PMCID： PMC4422091          DOI： 10.1038/bonekey.2015.28

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN： 2047-6396


× No keyword cloud information.
  20 in total

1.  Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis.

Authors:  Yanfei L Ma; Qingqiang Zeng; David W Donley; Louis-Georges Ste-Marie; J Christopher Gallagher; Gail P Dalsky; Robert Marcus; Erik Fink Eriksen
Journal:  J Bone Miner Res       Date:  2006-06       Impact factor: 6.741

2.  Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.

Authors:  Robert Lindsay; Hua Zhou; Felicia Cosman; Jeri Nieves; David W Dempster; Anthony B Hodsman
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

Review 3.  Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.

Authors:  Juliet E Compston
Journal:  Bone       Date:  2006-10-12       Impact factor: 4.398

4.  Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.

Authors:  David W Dempster; Hua Zhou; Robert R Recker; Jacques P Brown; Michael A Bolognese; Christopher P Recknor; David L Kendler; E Michael Lewiecki; David A Hanley; D Sudhaker Rao; Paul D Miller; Grattan C Woodson; Robert Lindsay; Neil Binkley; Xiaohai Wan; Valerie A Ruff; Boris Janos; Kathleen A Taylor
Journal:  J Clin Endocrinol Metab       Date:  2012-06-14       Impact factor: 5.958

5.  The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.

Authors:  Lorraine A Fitzpatrick; Christine E Dabrowski; Gregory Cicconetti; David N Gordon; Socrates Papapoulos; Henry G Bone; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2011-05-18       Impact factor: 5.958

6.  Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.

Authors:  D W Dempster; F Cosman; E S Kurland; H Zhou; J Nieves; L Woelfert; E Shane; K Plavetić; R Müller; J Bilezikian; R Lindsay
Journal:  J Bone Miner Res       Date:  2001-10       Impact factor: 6.741

7.  Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.

Authors:  Felicia Cosman; Tony M Keaveny; David Kopperdahl; Robert A Wermers; Xiaohai Wan; Kelly D Krohn; John H Krege
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

8.  Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

Authors:  Benjamin Z Leder; Joy N Tsai; Alexander V Uihlein; Sherri-Ann M Burnett-Bowie; Yuli Zhu; Katelyn Foley; Hang Lee; Robert M Neer
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

9.  Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

Authors:  Bruce Ettinger; Javier San Martin; Gerald Crans; Imre Pavo
Journal:  J Bone Miner Res       Date:  2004-01-19       Impact factor: 6.741

10.  Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

Authors:  Felicia Cosman; Robert A Wermers; Christopher Recknor; Karen F Mauck; Li Xie; Emmett V Glass; John H Krege
Journal:  J Clin Endocrinol Metab       Date:  2009-07-07       Impact factor: 5.958
View more
  3 in total

Review 1.  New horizons in treatment of osteoporosis.

Authors:  Ozra Tabatabaei-Malazy; Pooneh Salari; Patricia Khashayar; Bagher Larijani
Journal:  Daru       Date:  2017-02-07       Impact factor: 3.117

2.  Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation.

Authors:  L Osagie-Clouard; A Sanghani; M Coathup; T Briggs; M Bostrom; G Blunn
Journal:  Bone Joint Res       Date:  2017-01       Impact factor: 5.853

3.  High dose teriparatide (rPTH1-34) therapy increases callus volume and enhances radiographic healing at 8-weeks in a massive canine femoral allograft model.

Authors:  Kohei Nishitani; Zachary Mietus; Christopher A Beck; Hiromu Ito; Shuichi Matsuda; Hani A Awad; Nicole Ehrhart; Edward M Schwarz
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.